<p>Soleno Therapeutics, Inc.（纳斯达克代码：SLNO - 获取免费报告）的股票在周三的午盘交易中下跌了 3.4%。该公司的股价最低曾达到 48.50 美元，最后交易价为 48.40 美元。在午盘交易中，约有 379,566 股成交，较平均每日成交量 525,409 股下降了 28%。该股票此前收盘价为 50.11 美元。</p>
<p>获取 <strong>Soleno Therapeutics</strong> 的提醒：</p>
<h2>分析师评级变动</h2>
<p>SLNO 曾受到多份分析师报告的关注。Lifesci Capital 在 2 月 4 日的研究报告中将 Soleno Therapeutics 的评级上调至 “强力买入”。Stifel Nicolaus 在 3 月 5 日的研究报告中开始覆盖 Soleno Therapeutics，给予 “买入” 评级和 74.00 美元的目标价。HC Wainwright 在 3 月 3 日的研究报告中重申了 “买入” 评级，并给予 Soleno Therapeutics 70.00 美元的目标价。最后，Robert W. Baird 在 12 月 2 日的报告中重申了 “跑赢大盘” 评级，并给予 Soleno Therapeutics 72.00 美元的目标价。五位分析师对该股票给予了买入评级，两位分析师给予了强力买入评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “买入”，平均目标价为 71.20 美元。</p>
<p><strong>获取我们对 Soleno Therapeutics 的最新分析</strong></p>
<h2>Soleno Therapeutics 价格表现</h2>
<p>该股票的市值为 22.2 亿美元，市盈率为-14.55，贝塔值为-1.70。该公司的 50 日移动平均线为 47.43 美元，200 日移动平均线为 49.77 美元。</p>
<p>Soleno Therapeutics（纳斯达克代码：SLNO - 获取免费报告）最近在 3 月 5 日发布了季度财报。该公司报告的每股收益为（1.27 美元），低于分析师的共识预期（0.86 美元）0.41 美元。平均而言，股票研究分析师预计 Soleno Therapeutics, Inc.在本年度的每股收益将为-3.72 美元。</p>
<h2>内部人士下注</h2>
<p>在其他消息中，内部人士 Kristen Yen 在 1 月 3 日的交易中出售了 2,340 股公司的股票。该股票以平均价格 46.18 美元出售，总交易额为 108,061.20 美元。出售后，内部人士现在持有 76,605 股公司的股票，价值约为 3,537,618.90 美元。这代表其持股比例减少了 2.96%。该交易已在证券交易委员会的法律文件中披露，相关信息可通过 SEC 网站访问。此外，首席执行官 Bhatnagar Anish 在 1 月 2 日的交易中出售了 10,937 股公司的股票。该股票以平均价格 45.41 美元出售，总价值为 496,649.17 美元。出售后，首席执行官现在直接持有 708,616 股公司股票，价值 32,178,252.56 美元。这代表其持股比例减少了 1.52%。该交易的披露信息可在此处找到。内部人士在过去 90 天内出售了价值 790,119 美元的 17,360 股公司股票。公司内部人士持有 12.30% 的公司股票。</p>
<h2>Soleno Therapeutics 的机构交易</h2>
<p>一些大型投资者最近调整了对 SLNO 的持股。Victory Capital Management Inc.在第三季度将其在 Soleno Therapeutics 的持股增加了 25.9%。Victory Capital Management Inc.现在持有 13,509 股公司股票，价值 682,000 美元，此前在该期间内增持了 2,782 股。Intech Investment Management LLC 在第三季度购买了 Soleno Therapeutics 的新头寸，价值 262,000 美元。HealthInvest Partners AB 在第三季度购买了 Soleno Therapeutics 的新头寸，价值 1,332,000 美元。Charles Schwab Investment Management Inc.在第三季度将其在 Soleno Therapeutics 的持股增加了 208.1%。Charles Schwab Investment Management Inc.现在持有 192,597 股公司股票，价值 9,724,000 美元，此前在上个季度增持了 130,080 股。最后，Westfield Capital Management Co. LP 在第三季度购买了 Soleno Therapeutics 的新头寸，价值 25,028,000 美元。对冲基金和其他机构投资者持有公司 97.42% 的股票。</p>
<h2>关于 Soleno Therapeutics</h2>
<p>（获取免费报告）</p>
<p>Soleno Therapeutics, Inc.是一家临床阶段的生物制药公司，专注于开发和商业化用于治疗罕见疾病的新型疗法。其主要候选药物是氟氯噻吨缓释片，这是一种每日一次的口服药物，目前正在进行治疗普拉德 - 威利综合症的第三阶段临床试验。</p>
<h2>特色故事</h2>
<ul>
<li>五只我们更看好的股票，胜过 Soleno Therapeutics</li>
<li>卖空 - 利与弊</li>
<li>GTC 2025 对 NVIDIA 股票下一次重大走势的信号</li>
<li>如何计算期权利润</li>
<li>Alphabet 正式进入熊市——该买入了吗？</li>
<li>期权交易 - 理解行使价格</li>
<li>D-Wave 与量子霸权：对投资者的影响</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Soleno Therapeutics 吗？</h2>
<p>在考虑 Soleno Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Soleno Therapeutics 并不在名单上。</p>
<p>虽然 Soleno Therapeutics 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

Soleno治疗

<p>Soleno Therapeutics（纳斯达克代码：SLNO）股价在午盘交易中下跌 3.4%，至 48.40 美元，交易量较平均水平下降 28%。分析师的评级意见不一，Lifesci Capital 将其评级上调至 “强力买入”，其他分析师则将目标价设定在 70.00 美元至 74.00 美元之间。该公司报告的季度每股收益为（1.27 美元），未能达到预期。内部交易显示高管近期有出售股票的行为，而机构投资者持有 97.42% 的股份。Soleno 专注于开发罕见疾病的治疗方案，其主要候选药物正在进行普拉德 - 威利综合症的第三阶段临床试验</p>

<p>Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO - Get Free Report) dropped 3.4% during mid-day trading on Wednesday . The company traded as low as $48.50 and last traded at $48.40. Approximately 379,566 shares changed hands during mid-day trading, a decline of 28% from the average daily volume of 525,409 shares. The stock had previously closed at $50.11.</p>
<div class="lb-trans"><p>Soleno Therapeutics, Inc.（纳斯达克代码：SLNO - 获取免费报告）的股票在周三的午盘交易中下跌了 3.4%。该公司的股价最低曾达到 48.50 美元，最后交易价为 48.40 美元。在午盘交易中，约有 379,566 股成交，较平均每日成交量 525,409 股下降了 28%。该股票此前收盘价为 50.11 美元。</p>
</div><p>Get <strong>Soleno Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Soleno Therapeutics</strong> 的提醒：</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>SLNO has been the subject of a number of analyst reports. Lifesci Capital upgraded Soleno Therapeutics to a &#34;strong-buy&#34; rating in a research report on Tuesday, February 4th. Stifel Nicolaus initiated coverage on Soleno Therapeutics in a research report on Wednesday, March 5th. They issued a &#34;buy&#34; rating and a $74.00 price target for the company. HC Wainwright restated a &#34;buy&#34; rating and issued a $70.00 price target on shares of Soleno Therapeutics in a research report on Monday, March 3rd. Finally, Robert W. Baird reiterated an &#34;outperform&#34; rating and issued a $72.00 price objective on shares of Soleno Therapeutics in a report on Monday, December 2nd. Five analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of &#34;Buy&#34; and an average target price of $71.20.</p>
<div class="lb-trans"><p>SLNO 曾受到多份分析师报告的关注。Lifesci Capital 在 2 月 4 日的研究报告中将 Soleno Therapeutics 的评级上调至 “强力买入”。Stifel Nicolaus 在 3 月 5 日的研究报告中开始覆盖 Soleno Therapeutics，给予 “买入” 评级和 74.00 美元的目标价。HC Wainwright 在 3 月 3 日的研究报告中重申了 “买入” 评级，并给予 Soleno Therapeutics 70.00 美元的目标价。最后，Robert W. Baird 在 12 月 2 日的报告中重申了 “跑赢大盘” 评级，并给予 Soleno Therapeutics 72.00 美元的目标价。五位分析师对该股票给予了买入评级，两位分析师给予了强力买入评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “买入”，平均目标价为 71.20 美元。</p>
</div><p><strong>Get Our Latest Analysis on Soleno Therapeutics</strong></p>
<div class="lb-trans"><p><strong>获取我们对 Soleno Therapeutics 的最新分析</strong></p>
</div><h2>Soleno Therapeutics Price Performance</h2>
<div class="lb-trans"><h2>Soleno Therapeutics 价格表现</h2>
</div><p>The stock has a market capitalization of $2.22 billion, a price-to-earnings ratio of -14.55 and a beta of -1.70. The business has a fifty day moving average of $47.43 and a 200 day moving average of $49.77.</p>
<div class="lb-trans"><p>该股票的市值为 22.2 亿美元，市盈率为-14.55，贝塔值为-1.70。该公司的 50 日移动平均线为 47.43 美元，200 日移动平均线为 49.77 美元。</p>
</div><p>Soleno Therapeutics (NASDAQ:SLNO - Get Free Report) last released its quarterly earnings results on Wednesday, March 5th. The company reported ($1.27) EPS for the quarter, missing analysts' consensus estimates of ($0.86) by ($0.41). On average, equities research analysts expect that Soleno Therapeutics, Inc. will post -3.72 EPS for the current year.</p>
<div class="lb-trans"><p>Soleno Therapeutics（纳斯达克代码：SLNO - 获取免费报告）最近在 3 月 5 日发布了季度财报。该公司报告的每股收益为（1.27 美元），低于分析师的共识预期（0.86 美元）0.41 美元。平均而言，股票研究分析师预计 Soleno Therapeutics, Inc.在本年度的每股收益将为-3.72 美元。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In other news, insider Kristen Yen sold 2,340 shares of the company's stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $46.18, for a total transaction of $108,061.20. Following the sale, the insider now owns 76,605 shares of the company's stock, valued at approximately $3,537,618.90. This represents a 2.96 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. Also, CEO Bhatnagar Anish sold 10,937 shares of the company's stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $45.41, for a total value of $496,649.17. Following the sale, the chief executive officer now directly owns 708,616 shares in the company, valued at $32,178,252.56. This represents a 1.52 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 17,360 shares of company stock worth $790,119 over the last ninety days. Corporate insiders own 12.30% of the company's stock.</p>
<div class="lb-trans"><p>在其他消息中，内部人士 Kristen Yen 在 1 月 3 日的交易中出售了 2,340 股公司的股票。该股票以平均价格 46.18 美元出售，总交易额为 108,061.20 美元。出售后，内部人士现在持有 76,605 股公司的股票，价值约为 3,537,618.90 美元。这代表其持股比例减少了 2.96%。该交易已在证券交易委员会的法律文件中披露，相关信息可通过 SEC 网站访问。此外，首席执行官 Bhatnagar Anish 在 1 月 2 日的交易中出售了 10,937 股公司的股票。该股票以平均价格 45.41 美元出售，总价值为 496,649.17 美元。出售后，首席执行官现在直接持有 708,616 股公司股票，价值 32,178,252.56 美元。这代表其持股比例减少了 1.52%。该交易的披露信息可在此处找到。内部人士在过去 90 天内出售了价值 790,119 美元的 17,360 股公司股票。公司内部人士持有 12.30% 的公司股票。</p>
</div><h2>Institutional Trading of Soleno Therapeutics</h2>
<div class="lb-trans"><h2>Soleno Therapeutics 的机构交易</h2>
</div><p>A number of large investors have recently modified their holdings of SLNO. Victory Capital Management Inc. increased its position in shares of Soleno Therapeutics by 25.9% during the third quarter. Victory Capital Management Inc. now owns 13,509 shares of the company's stock worth $682,000 after acquiring an additional 2,782 shares during the period. Intech Investment Management LLC purchased a new position in Soleno Therapeutics in the third quarter valued at $262,000. HealthInvest Partners AB purchased a new position in Soleno Therapeutics in the third quarter valued at $1,332,000. Charles Schwab Investment Management Inc. increased its holdings in Soleno Therapeutics by 208.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 192,597 shares of the company's stock valued at $9,724,000 after buying an additional 130,080 shares during the last quarter. Finally, Westfield Capital Management Co. LP purchased a new position in Soleno Therapeutics in the third quarter valued at $25,028,000. Hedge funds and other institutional investors own 97.42% of the company's stock.</p>
<div class="lb-trans"><p>一些大型投资者最近调整了对 SLNO 的持股。Victory Capital Management Inc.在第三季度将其在 Soleno Therapeutics 的持股增加了 25.9%。Victory Capital Management Inc.现在持有 13,509 股公司股票，价值 682,000 美元，此前在该期间内增持了 2,782 股。Intech Investment Management LLC 在第三季度购买了 Soleno Therapeutics 的新头寸，价值 262,000 美元。HealthInvest Partners AB 在第三季度购买了 Soleno Therapeutics 的新头寸，价值 1,332,000 美元。Charles Schwab Investment Management Inc.在第三季度将其在 Soleno Therapeutics 的持股增加了 208.1%。Charles Schwab Investment Management Inc.现在持有 192,597 股公司股票，价值 9,724,000 美元，此前在上个季度增持了 130,080 股。最后，Westfield Capital Management Co. LP 在第三季度购买了 Soleno Therapeutics 的新头寸，价值 25,028,000 美元。对冲基金和其他机构投资者持有公司 97.42% 的股票。</p>
</div><h2>About Soleno Therapeutics</h2>
<div class="lb-trans"><h2>关于 Soleno Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.</p>
<div class="lb-trans"><p>Soleno Therapeutics, Inc.是一家临床阶段的生物制药公司，专注于开发和商业化用于治疗罕见疾病的新型疗法。其主要候选药物是氟氯噻吨缓释片，这是一种每日一次的口服药物，目前正在进行治疗普拉德 - 威利综合症的第三阶段临床试验。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>特色故事</h2>
</div><ul>
<li>Five stocks we like better than Soleno Therapeutics</li>
<li>Short Selling - The Pros and Cons</li>
<li>What GTC 2025 Signals for NVIDIA Stock’s Next Big Move</li>
<li>How to Calculate Options Profits</li>
<li>Alphabet’s Officially In A Bear Market—Time To Buy?</li>
<li>Options Trading - Understanding Strike Price</li>
<li>D-Wave and Quantum Supremacy: Implications For Investors</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Soleno Therapeutics</li>
<li>卖空 - 利与弊</li>
<li>GTC 2025 对 NVIDIA 股票下一次重大走势的信号</li>
<li>如何计算期权利润</li>
<li>Alphabet 正式进入熊市——该买入了吗？</li>
<li>期权交易 - 理解行使价格</li>
<li>D-Wave 与量子霸权：对投资者的影响</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Soleno Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Soleno Therapeutics 吗？</h2>
</div><p>Before you consider Soleno Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Soleno Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Soleno Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Soleno Therapeutics 并不在名单上。</p>
</div><p>While Soleno Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Soleno Therapeutics 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Soleno 治疗 (NASDAQ:SLNO) 股价下跌 3.4% - 你应该卖出吗？